
miRNA and Cancer
Description
Key Features
- Provides information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Readership
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology
Table of Contents
1. MicroRNAs and Cancer: A Long Story for Short RNAs
Alessandra Drusco and Carlo M. Croce
2. The Enigma of miRNA Regulation in Cancer
Anjan K. Pradhan, Luni Emdad, Swadesh K. Das, Devanand Sarkar and Paul B. Fisher
3. Animal Models to Study microRNA Functions
Arpita S. Pal and Andrea L. Kasinski
4. Cancer Hallmarks and MicroRNAs: The Therapeutic Connection
Katrien Van Roosbroeck and George A. Calin
5. microRNAs in Cancer Susceptibility
Brid M. Ryan
6. Role of the tRNA-Derived Small RNAs in Cancer: New Potential Biomarkers and Target for Therapy
Veronica Balatti, Yuri Pekarsky and Carlo M. Croce
7. MicroRNAs and Epigenetics
Catia Moutinho and Manel Esteller
Product details
- No. of pages: 230
- Language: English
- Copyright: © Academic Press 2017
- Published: September 2, 2017
- Imprint: Academic Press
- Hardcover ISBN: 9780128119228
- eBook ISBN: 9780128119235
About the Series Editor
Kenneth Tew

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
Affiliations and Expertise
About the Serial Volume Editors
Paul Fisher
